Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition
Journal of Medicinal Chemistry · 09.07.2026 · 69 (13) · 15510-15530
DOI: 10.1021/acs.jmedchem.6c00353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.06.2026. Verfasst von Kaizhen Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Nicotinamide Phosphoribosyltransferase, Cytokines, Antineoplastic Agents. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Inhibition of the Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) represents a promising therapeutic strategy for cancer. However, resistance to SHP2 inhibition, mediated by multiple mechanisms, has limited the clinical efficacy of SHP2 inhibitor monotherapy. Herein, we identified that nicotinamide phosphoribosyltransferase (NAMPT) inhibition could potentially overcome resistance to SHP2 inhibition in tumor cells. Compound A4 was identified as the most potent dual inhibitor targeting SHP2 and NAMPT, exhibiting high inhibitory activity against both SHP2 and NAMPT. A4 effectively inhibited proliferation in SHP099-insensitive tumor cell lines and reversed programmed cell death ligand 1 (PD-L1)-mediated immunosuppression. Furthermore, A4 displayed significant in vivo antitumor efficacy in an MDA-MB-231 mouse model and strongly promoted in vivo antitumor immunity in a 4T1 mouse model. Our results identified A4 as a promising dual SHP2 and NAMPT inhibitor, providing a novel therapeutic strategy for overcoming resistance to allosteric SHP2 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- School of Biomedical Engineering, Tsinghua University, Beijing 100084, China.
ORCID-Profile: Sheng Jiang, Xiangyu Zhang, Kuojun Zhang, Tianyu Wang
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Wang, K., Liu, Y., Zhang, Z., Hu, Y., Zhong, Y., Jiang, S., Zhang, X., Zhang, K., & Wang, T. (2026). Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of Medicinal Chemistry, 69(13), 15510-15530. https://doi.org/10.1021/acs.jmedchem.6c00353
Vancouver
Wang K, Liu Y, Zhang Z, Hu Y, Zhong Y, Jiang S, et al. Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of Medicinal Chemistry. 2026;69(13):15510-15530. doi:10.1021/acs.jmedchem.6c00353
BibTeX
@article{Wang2026,
author = {Wang, Kaizhen and Liu, Yijiao and Zhang, Zhiyi and Hu, Yingxin and Zhong, Yuhua and Jiang, Sheng and Zhang, Xiangyu and Zhang, Kuojun and Wang, Tianyu},
title = {Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {13},
pages = {15510--15530},
doi = {10.1021/acs.jmedchem.6c00353}
}
EUVIMED